A Study of Patients With Fabry Disease (US Specific)

This observational study is following patients with Fabry disease in the United States who are being treated with migalastat (a pill that helps the body's enzyme system work better) or enzyme replacement therapy, to track how well the treatments work over time in real-world settings. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of Fabry disease - You have an amenable genetic variant (your specific mutation responds to migalastat) and are taking or starting migalastat commercially, OR you are receiving enzyme replacement therapy (ERT) - Your kidney function is adequate (eGFR ≥ 30 mL/min/1.73 m²) - You have not previously participated in a migalastat clinical trial **You may NOT be eligible if...** - You do not have a confirmed Fabry disease diagnosis - Your kidney function is below the minimum threshold - You are enrolled in another interventional clinical trial Talk to your doctor to see if this trial is right for you.